Evergreen Theragnostics
Springfield, New Jersey, United States
Hybrid — also manufactures internal programs
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: Evergreen Theragnostics
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- Springfield, New Jersey, United States
- Website
- https://www.evergreentgn.com/
- Modalities
- Radiopharmaceuticals
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Evergreen Theragnostics
Evergreen Theragnostics makes its own pharmaceutical products and also offers contract development and manufacturing services. Capabilities: Radiopharmaceuticals. 1 manufacturing site registered with the U.S. FDA. Website: https://www.evergreentgn.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Oct 30, 2026
Company Signals 9 articles
Company announcements, not verified evidence. They do not change any score.
LNTH: Evergreen Acquisition Promotes Future Innovation - scr.zacks.com
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront - Medical Marketing and Media
Lantheus Holdings to Acquire Evergreen Theragnostics - Contract Pharma
Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen - Fierce Pharma
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader - PR Newswire
Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services - PR Newswire
Evergreen Theragnostics Raises $26M in Capital to Aid Commercialization Efforts for the Ga-68 DOTATOC Diagnostic Kit - Pharmaceutical Commerce
Evergreen Theragnostics Completes $15M Series B, Launches Discovery Unit, and Prepares Ga-68 DOTATOC Supply Chain - PR Newswire
Frequently Asked Questions About Evergreen Theragnostics
Does Evergreen Theragnostics have a CDMO Signal Score?
Not yet. Evergreen Theragnostics is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Evergreen Theragnostics for a manufacturing program?
Use the free AI matchmaker to compare Evergreen Theragnostics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
NorthStar Medical Radioisotopes
Beloit, Wisconsin, United States
Radiopharmaceuticals
SpectronRx
South Bend, Indiana, United States
Radiopharmaceuticals
Agilera Pharma
Norway (registered site)
Radiopharmaceuticals
ABX advanced biochemical compounds
Germany
Radiopharmaceuticals
AtomVie Global Radiopharma
Canada
Radiopharmaceuticals
Compare Evergreen Theragnostics with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.